NCT05043298View on ClinicalTrials.gov

A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 27, 2021

Primary Completion Date

August 30, 2023

Study Completion Date

August 30, 2023

Conditions
Advanced Solid Tumor
Interventions
DRUG

IBI 360 Injection

IBI 360 dose level of escalation IV Q3W Day 1

DRUG

IBI 360 Injection Sintilimab

IBI 360 dose level of escalation IV Q3W Day 1 Sintilimab 200mg IV Q3W Day 1

Trial Locations (1)

215000

Innovent Biologics (suzhou) Co. , Ltd., Suzhou

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT05043298 - A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter